金属蛋白酶2组织抑制剂在乳腺癌组织中的表达

目的：探讨金属蛋白酶2组织抑制剂（TIMP-2）在乳腺癌组织中的表达特点及其与临床病理参数的关系。方法：采用免疫组织化学SP法，检测62例乳腺癌组织中TIMP-2的表达情况。结果：乳腺癌组织中TIMP-2阳性表达率为64．52％。TIMP-2阳性表达率在≤50岁年龄组（51．52％）比〉50岁患者年龄组阳性率（79．31％）明显偏低（P〈0．05）。浸润性导管癌的阳性表达率（71．15％）明显高于导管内癌局部浸润的阳性表达率（30．00％）（P〈0．05）。无淋巴结转移组阳性率（78．38％）明显高于有淋巴结转移组（44．00％）（P〈0．05）。TIMP-2阳性表达与癌的左右乳分布及临床分期没有显著性差异（P〉0．05）。结论：在乳腺癌组织中TIMP-2表达降低，可能促进了乳腺癌的浸润进展及转移，金属蛋白酶抑制剂的研治将为乳腺癌的临床治疗开辟新途径。

Expression of TIMP-2 in breast carcinoma tissues

Objective：To explore the expression characteristic of tissue inhibitor of metalloproteinase （TIMP）-2 in breast carcinomas and its relationship to pathoclinical parameters. Methods： TIMP-2 expression was detected by SP immunohistochemistry in 62 cases of breast carcinoma tissues. Results： The positive rate of TIMP-2 expression in breast carcinoma tissues was 64.52%. The positive rate in ≤50 year old age group （51. 52%） was obviously lower than 〉50 year old group （79.31%） （P〈0. 05）. Expression rate in invasive ductal carcinoma （71.15%） was obviously higher than local invasive ductal carcinoma in situ （30.00%）（P〈0. 05）. And the positive rate of non-lymph node metastasis group （78.38%） was obviously higher than the lymph node metastasis group （44.00%）（P〈0. 05）. TIMP-2 expression showed no correlation with position of cancer or clinical stages （P〉0. 05） . Conclusion： Down-regulation of TIMP-2 expression in breast carcinoma may promote its invasion and metastasis in the progression. Research of new inhibitors of MMPs may open the new way for the clinical treatment of breast cancer.